- Home
- FCBC vs PHAR Comparison
FCBC vs PHAR Comparison
Compare FCBC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCBC
- PHAR
- Stock Information
- Founded
- FCBC 1874
- PHAR 1988
- Country
- FCBC United States
- PHAR Netherlands
- Employees
- FCBC N/A
- PHAR N/A
- Industry
- FCBC Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- FCBC Finance
- PHAR Health Care
- Exchange
- FCBC Nasdaq
- PHAR Nasdaq
- Market Cap
- FCBC 681.6M
- PHAR 718.1M
- IPO Year
- FCBC 1992
- PHAR N/A
- Fundamental
- Price
- FCBC $38.81
- PHAR $10.79
- Analyst Decision
- FCBC Hold
- PHAR Strong Buy
- Analyst Count
- FCBC 1
- PHAR 3
- Target Price
- FCBC $38.00
- PHAR $30.00
- AVG Volume (30 Days)
- FCBC 61.0K
- PHAR 2.5K
- Earning Date
- FCBC 07-22-2025
- PHAR 07-31-2025
- Dividend Yield
- FCBC 3.19%
- PHAR N/A
- EPS Growth
- FCBC 3.83
- PHAR N/A
- EPS
- FCBC 2.74
- PHAR N/A
- Revenue
- FCBC $162,590,000.00
- PHAR $320,708,000.00
- Revenue This Year
- FCBC $2.34
- PHAR $13.31
- Revenue Next Year
- FCBC $1.10
- PHAR $7.68
- P/E Ratio
- FCBC $14.16
- PHAR N/A
- Revenue Growth
- FCBC 1.13
- PHAR 24.13
- 52 Week Low
- FCBC $33.84
- PHAR $6.65
- 52 Week High
- FCBC $49.02
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- FCBC 56.16
- PHAR 50.86
- Support Level
- FCBC $36.81
- PHAR $10.23
- Resistance Level
- FCBC $39.60
- PHAR $11.21
- Average True Range (ATR)
- FCBC 0.82
- PHAR 0.31
- MACD
- FCBC 0.14
- PHAR -0.15
- Stochastic Oscillator
- FCBC 71.68
- PHAR 32.51
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.